Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: Ish who wrote (15647)	11/8/2003 9:00:49 PM
From: LindyBill	Read Replies (1) \| Respond to of 793698

He's 100% German origin. If you are dark complected, doing that would be one hell of a pickup line for a guy. "I'm from Tonga. Son of the Chief"

To: Ish who wrote (15647)	11/8/2003 9:43:07 PM
From: DMaA	Read Replies (3) \| Respond to of 793698

I used to work with a Japanese/American guy who was always being mistaken for Mexican.

To: Ish who wrote (15647)	11/8/2003 9:43:56 PM
From: LindyBill	Respond to of 793698

The Drug Industry's Holy Grail By GINA KOLATA - NEW YORK TIMES If the drug industry has a commercial Holy Grail, it might be an anti-aging pill, one that would let you live longer and prolong your youthful vigor. The market would be huge, of course. The problem is that to get it approved by the Food and Drug Administration, researchers would have to find a way to demonstrate that it works. To prove it was safe and effective, a company would have to give it to people and then wait to see if they lived longer than a control group that did not take the drug. The researchers might have to wait decades, by which time their patent protection rights — 17 years, by current law — would be long gone. The company would pay the costs of research and development, and the generic drug industry would reap the benefits. "It's a bear of a problem," said Dr. Leonard P. Guarente, a biology professor at the Massachusetts Institute of Technology and a founder of Elixir Pharmaceuticals, which, according to its Web site, seeks "therapeutics that slow aging, forestall the disease and disability that accompany aging, and extend life's most productive period." The company is pinning its hopes on a gene that is turned on with very low-calorie diets. This gene's activity, Dr. Guarente said, is the reason such a diet, if someone could stand it, might prolong life. The company's aim is to find a drug that will turn up the activity of the gene, SIRT1, giving the effect of a diet without having to be on one. But then what? nytimes.com